The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Summary of the document prepared by the Czech Society of Cardiology

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F18%3A73592003" target="_blank" >RIV/61989592:15110/18:73592003 - isvavai.cz</a>

Alternative codes found

RIV/00023001:_____/18:00077230

Result on the web

<a href="https://e-coretvasa.cz/pdfs/cor/2018/04/20.pdf" target="_blank" >https://e-coretvasa.cz/pdfs/cor/2018/04/20.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.crvasa.2018.05.001" target="_blank" >10.1016/j.crvasa.2018.05.001</a>

Result language

angličtina

Original language name

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Summary of the document prepared by the Czech Society of Cardiology

Original language description

Introduction Non-vitamin K antagonist oral anticoagulants (NOACs) have emerged as an alternative for vitamin K antagonists (VKAs) for thrombo-embolic prevention in patients with non-valvular atrial fibrillation (AF). Some authors refer to these drugs as ‘direct oral anticoagulants’ (DOACs), but since the term NOAC has been used for many years and is widely recognized, we prefer to continue to use NOAC. Non-vitamin K antagonist oral anticoagulants have an improved efficacy/safety ratio, predictable effect without need for routine monitoring, and fewer food and drug interactions compared with VKAs. However, the proper use of NOACs requires different approaches to many practical aspects compared with VKAs. The European Heart Rhythm Association (EHRA) set out to coordinate a unified way of informing physicians on the use of NOACs. A first Practical Guide was published in 2013 to supplement the AF guidelines as a guidance for safe, effective use of NOAC when prescribed. This text is a first update to the original Guide. A writing group formulated practical answers to 15 clinical scenarios, based on available and updated knowledge. In some instances, the authors opted to make recommendations that do not fully align with all SmPC, with the goal to provide more uniform and simple practical advice. An EHRA website, www.NOACforAF.eu, accompanies the Practical Guide. Definition of “non-valvular atrial fibrillation” and eligibility for non-vitamin K antagonist oral anticoagulants Non-valvular AF refers to AF that occurs in the absence of mechanical prosthetic heart valves and in the absence of moderate to severe mitral stenosis (usually of rheumatic origin) (Table 1). Both types of patients were excluded from all NOAC trials. Mechanical prosthetic heart valves constitute a strict contraindication for the use of any NOAC until further data become available.

Czech name

—

Czech description

—

Type

J_SC - Article in a specialist periodical, which is included in the SCOPUS database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

COR ET VASA

ISSN

0010-8650

e-ISSN

—

Volume of the periodical

60

Issue of the periodical within the volume

4

Country of publishing house

PL - POLAND

Number of pages

26

Pages from-to

"E421"-"E446"

UT code for WoS article

000442902500014

EID of the result in the Scopus database

2-s2.0-85051662246